|
|
Blood, 15 October 2005, Vol. 106, No. 8, pp. 2700-2709.
Prepublished online as a Blood First Edition Paper on May 3, 2005; DOI 10.1182/blood-2005-01-0330.
 Previous Article | Next Article 
Submitted January 25, 2005
Accepted April 21, 2005
Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation
Laisvyde Statkute, Ann Traynor, Yu Oyama, Kim Yaung, Larissa Verda, Nela Krosnjar, and Richard K Burt*
Division of Immunotherapy, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
* Corresponding author; email: rburt{at}northwestern.edu.
Systemic lupus erythematosus (SLE) is the most common disease associated with antiphospholipid syndrome (APS). We, therefore, evaluated 46 patients with refractory SLE treated by autologous hematopoietic stem cell transplantation (HSCT) for a history of pre-transplant APS. The prevalence of SLE-related APS in our patient population was 61% (28 out of 46 patients with refractory SLE). Nineteen of 28 patients with APS had lupus anticoagulant (LA) and /or high titers of anticardiolipin antibodies (ACLA), either IgG and/or IgM, when evaluated at study entry. Six of eight evaluable LA-positive patients became and remained LA-negative; five of seven initially ACLA IgG-positive patients and nine of eleven ACLA IgM-positive patients demonstrated normalization of ACLA titers when followed after HSCT. Eighteen out of 22 patients refractory to chronic anticoagulation discontinued anticoagulation therapy a median of 4 months post-transplant; 78% of them remained thrombotic event-free and in complete SLE remission for up to 78 months (median 15 months) after HSCT. There was no treatment-related mortality. Autologous HSCT may be performed safely in patients with APS and appears to be effective therapy for eliminating ALPA and preventing thrombotic complications in SLE patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Transplantation for SLE?
- Steven Z. Pavletic
Blood 2005 106: 2597.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
F. Braiteh, S. R. Hymes, S. A. Giralt, and R. Jones
Complete Remission of Psoriasis After Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
J. Clin. Oncol.,
September 20, 2008;
26(27):
4511 - 4513.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Ruckert, H Glimm, M Lubbert, and C Grullich
Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up
Lupus,
August 1, 2008;
17(8):
757 - 760.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. A. Garcia, M. A. Khamashta, and M. A. Crowther
How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review
Blood,
November 1, 2007;
110(9):
3122 - 3127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Hill and D. Nochy
Antiphospholipid Syndrome in Systemic Lupus Erythematosus
J. Am. Soc. Nephrol.,
September 1, 2007;
18(9):
2461 - 2464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Burt, A. Traynor, L. Statkute, W. G. Barr, R. Rosa, J. Schroeder, L. Verda, N. Krosnjar, K. Quigley, K. Yaung, et al.
Nonmyeloablative Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus
JAMA,
February 1, 2006;
295(5):
527 - 535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
